

The relationship between Vitamin D deficiency and polycystic ovary syndrome

Feyzi Gokosmanoglu¹, Attila Onmez², Hasan Ergenc³

1. Department of Endocrinology, Ordu Medical Park Hospital, Ordu, Turkey.
2. Department of Internal Medicine, Duzce University Medicine Faculty, Düzce, Turkey.
3. Department of Internal Medicine, Sinop Ayancık State Hospital, Sinop, Turkey.

Emails:

Feyzi Gokosmanoglu: Tel: +90 505 7512117 e-mail: gokosmanoglu@gmail.com; Hasan Ergenc: Tel: +90 535 8382022 e-mail: dr.hasanergenc@hotmail.com

Abstract

Background: Vitamin D deficiency is frequently seen in patients with polycystic ovary syndrome (PCOS) and has been shown to exhibit multiple effects on the disease process. The purpose of this study was to investigate the role of vitamin D deficiency in complex PCOS pathophysiological pathways.

Methods: Two hundred sixty-seven patients with PCOS were divided into two groups Group 1 with 25(OH)D3 deficiency, and Group 2 with normal 25(OH)D3. Biochemical and hormonal parameters (androgen hormones, gonadotropins, and thyroid function tests) were compared between the two groups.

Results: Eighty-six percent of the patients (n=231) were in Group 1 and 14% (n=36) in Group 2. Statistically significantly higher concentrations of serum testosterone, dehydroepiandrosterone-sulfate and LH were determined in Group 1 ($p < 0.05$). 25(OH)D3 concentrations were negatively correlated with body mass index ($r = -0.459$), serum testosterone ($r = -0.374$) and dehydroepiandrosterone-sulfate levels ($r = -0.418$); (all; $p < 0.05$).

Conclusion: The study findings show that low 25(OH)D3 levels are associated with high androgen levels in women with PCOS. Vitamin D deficiency should be considered as an additional risk factor in the development of PCOS. We think that providing vitamin D supplementation for women from identified deficiency areas can reduce the risk of PCOS development.

Keywords: Polycystic ovarian syndrome; vitamin D deficiency; androgen hormones; testosterone

DOI: <https://dx.doi.org/10.4314/ahs.v20i4.45>

cite as: Gokosmanoglu F, Onmez A, Ergenc H. The relationship between Vitamin D deficiency and polycystic ovary syndrome. *Afri Health Sci.* 2020;20(4):1880-6. <https://dx.doi.org/10.4314/ahs.v20i4.45>

Introduction

Polycystic ovary syndrome (PCOS) is an endocrine disease frequently seen in women of reproductive age. PCOS is characterized by polycystic ovarian morphology, hyperandrogenism, and ovulatory impairment¹. The etiology of PCOS is still unclear. However, evidence suggests a multi-factorial origin, with expression being seen in women with a genetic disposition². The basic finding in the pathophysiology of PCOS is insulin resistance³. This develops in association with weight gain

and an increase in waist circumference and is powerfully associated with hyperandrogenemia and ovarian dysfunction⁴. Obesity and insulin resistance aggravate hyperandrogenemia⁵. The incidence of cardiovascular diseases, type 2 diabetes mellitus, hypertension, endometrial cancer, and inflammation-related conditions increases in association with increased adipose tissue and hyperandrogenemia in women with PCOS^{6,7,8}.

Vitamin D deficiency also increases the risk of numerous chronic medical conditions such as obesity, cardiovascular disease, type 2 diabetes, malignancy, autoimmunity, infectious disease, and psychological disorder⁹. Obesity is a well-recognized risk factor for vitamin D deficiency¹⁰. A negative correlation between body mass index and serum 25(OH)D3 concentrations has been shown in women with PCOS in previous reports¹¹. Vitamin D receptor (VDR) is expressed in several tissues other than skeletal muscle. It is therefore associated

Corresponding author:

Attila Onmez,
Duzce Tıp Fakultesi,
Yörükler Mah. Konuralp yerleşkesi,
81620 Merkez/Düzce Merkez/Düzce
Tel: +90 380 542 14 16
Fax: +90 380 542 13 02
E-mail: attilaonmez@gmail.com

with glucose metabolism, in addition to the well-known calcium-bone metabolism, the cardiovascular system, malignancies, and female reproductive tissues such as the ovaries, placenta, endometrium, and fallopian tubes¹².

The relationship between PCOS and vitamin D has already been the subject of various previous studies. Vitamin D deficiency may increase the risk of PCOS¹³. Another study showed that vitamin D support improves blood pressure profiles and reduces insulin resistance, and total testosterone and androstenedione levels in patients with PCOS¹⁴. Lower vitamin D levels have been reported in obese women with PCOS compared to non-obese PCOS patients¹⁵. Impaired glucose tolerance and an increased risk of type 2 diabetes development occur with increasing insulin resistance in PCOS, and an increased risk of type 2 diabetes has been shown in vitamin D deficiency¹⁷. One meta-analysis also reported that the incidence of PCOS increased in vitamin D deficiency, and that this also leads to metabolic and endocrine dysfunction¹⁸.

The prevalence of PCOS is growing. Understanding the mechanism involved may help elucidate the pathophysiology of the syndrome. It is important to identify effective diagnostic and treatment methods in order to better identify the causes of PCOS. The purpose of the present study was to evaluate the association between serum vitamin D deficiency and the risk of disease, and to analyze the relationships with metabolic and endocrine disorders in women with PCOS in our own population.

Methods

This study involved patients followed-up with diagnosis of PCOS at the Medical Park Hospital endocrinology and gynecology clinics, Ordu, Turkey, between January 2015 and September 2019. Two hundred sixty-seven Caucasian women of reproductive age between 18 and 40 with PCOS were included in the study.

Diagnosis of PCOS was based on the ESHRE/ASRM (Rotterdam) 2004 criteria¹⁹. These consisted of the presence of at least two of ovulation abnormalities such as oligo-ovulation or anovulation, clinical signs of hyperandrogenism and/or biochemical hyperandrogenism, and polycystic ovarian morphology. Patients' ages, anthropometric measurements, Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) values, lipid profiles, androgen hormones, and thyroid function tests were analyzed.

Exclusion criteria included a history of autoimmune disease, presence of collagen tissue disease, pregnancy, or immunosuppressive medication use, history of diabetes, coronary heart disease, hyperlipidemia, or liver and kidney organ failure, age under 18 or over 40, and menopausal status. Such cases were not included in the study.

All participants underwent physical examination, and their weight, height, and waist circumference (WC) measurements were recorded. Body mass index (BMI) was calculated by dividing weight (in kilograms) by height (in meters) squared. WC measurements were performed at the level of the iliac processes and umbilicus.

Subjects were studied after overnight fasting, and blood specimens were collected at approximately 08:00 hours for the measurement of serum fasting glucose (cut-off level 70-100 mg/dl), fasting insulin (cut-off level 2-5 IU / mL), 25 (OH)D3 (cut-off level 30-50 ng/mL), FSH (cut-off level 1.5 – 12.4 mIU/mL), LH (cut-off level 2.00-15.00 mIU/mL), serum testosterone (cut-off level 3.5-8.6 ng/ml, DHEA-S (cut-off level 82-338 ng/dL), and PRL (cut-off level 2-20 ng/mL) using automated chemiluminescence immunoassay (ICMA) kits (Abbott, IL, USA). Serum 25(OH)D3 levels were used to evaluate vitamin D status. HOMA-IR was calculated using the formula fasting plasma insulin (mg/dL) x fasting plasma glucose (U/mL) / 405.

25 (OH) D3 values were measured using commercial euglobulin clot lysis assay (ECLA) kits (Roche, Germany). Based on Endocrine Society criteria, 25(OH)D3 status was defined as vitamin D deficiency (<20 ng/mL), insufficiency (21-29 ng/mL) or sufficiency (\geq 30 ng/mL)²⁰. The patients in the present study were divided into two groups - group I: 25(OH)D3 <29 ng/mL and Group II: 25(OH)D3 \geq 30 ng/mL.

Pelvic ultrasonography was carried out using a high-resolution apparatus (Philips Affinity 70 ultrasound, Philips North America Corporation 3000 Andover, MA, USA) equipped with a 5-1 MHz broadband convex series probe.

This study was conducted in accordance with the principles enshrined in the Declaration of Helsinki. All participating women gave written informed consent prior to inclusion in the study. The study protocols were approved by the Ordu University Medical Faculty ethical committee.

Statistical analysis

The study data were analyzed on SPSS version 20.0 software (IBM Corp., USA). Quantitative parametric data were expressed as mean plus standard deviation (SD). The Kolmogorov–Smirnov test was used to analyze the distribution of variables. For non-parametric data, intergroup comparisons were performed using the Mann-Whitney U test, while the independent-t test was used to compare parametric data between the groups. Categorical variables were evaluated using the Pearson Chi-Square Test. Correlations between serum 25(OH)VD3 concentrations, androgen hormones, BMI, waist circumference, HOMA-IR index, thyroid function test, and age were analyzed using Pearson's correlation co-

efficient. p values <0.05 were regarded as statistically significant.

Results

Two hundred sixty-seven patients aged between 18 and 45 (Group 1=231, Group 2=36) were included in the study. Patients' demographic, clinical, biochemical and metabolic characteristics are given in Table 1. All patients were diagnosed with PCOS. Age and triglyceride and LDL-C levels were similar between the two groups. BMI, fasting glucose, HOMA-IR values were statistically significantly higher in Group 1 (25(OH)D₃ = 0-29 ng/mL), while Vitamin D, calcium, and HDL-cholesterol levels were higher in Group 2 (25(OH)D₃ \geq 30 ng/mL) (Table 1).

Table 1: Patients' clinical, biochemical and metabolic data

Parameters	PCOS		P value
	Group I	Group II	
	25(OH)D ₃ Deficiency (\leq 29 ng/mL) (n=231)	25(OH)D ₃ Normal (\geq 30 ng/mL) (n=36)	
Age(years) mean \pm SD	28.7 \pm 5	29.6 \pm 6	0.932
BMI, kg/m ²	29.1 \pm 4.6	25.8 \pm 2.4	0.012
Waist circumference (cm)	91.5 \pm 12.6	82 \pm 10.1	0.031
Fasting glucose, mg/dl	92.5 \pm 12.3	80.1 \pm 10.1	0.025
HOMA-IR	3.7 \pm 1.2	3.3 \pm 0.8	0.037
25 (OH) D ₃ ng/mL	12.8 \pm 3.3	34 \pm 7.6	0.000
Serum calcium, mg/dL	8.2 \pm 2.8	9.6 \pm 4.1	0.029
Triglyceride, mg/dl	142.8 \pm 23.1	136.9 \pm 17.6	0.052
LDL-C, mg/dl	143.5 \pm 25	144.1 \pm 25.2	0.983
HDL-C, mg/dl	40.4 \pm 8.8	49.7 \pm 9.2	0.031

BMI; Body Mass Index. HOMA-IR; Homeostasis Model Assessment Insulin - Resistance Index. LDL-C; LDL-Cholesterol. HDL-C; HDL-Cholesterol. Significant results are shown in bold type.

Serum testosterone, DHEA-S and LH levels were statistically significantly higher in Group 1 ($p < 0.05$). FSH, PRL, TSH, and fT4 values were at similar levels in the two groups, as seen in Table 2. However, PRL and TSH levels were lower in patients with normal Vitamin D levels, although the differences were not statistically significant ($p > 0.05$).

We observed negative correlation between serum

25(OH)VD3 concentrations and BMI ($p = 0.002$), fasting glucose ($p = 0.031$) waist circumference ($p = 0.023$), HOMA-IR ($p = 0.006$), LH ($p = 0.027$), serum testosterone ($p = 0.012$), and DHEAS ($p = 0.003$) in women with PCOS. No correlation was found between 25(OH)D₃ levels and age, FSH, TSH, or sT4 levels in women with PCOS ($p > 0.05$). Correlation analysis is summarized in Table 3.

Table 2: Comparison of the two groups' hormonal parameters

Parameters	PCOS		P value
	Group I	Group II	
	25(OH)D ₃ Deficiency (≤ 29 ng/mL) (n=231)	25(OH)D ₃ Normal (≥ 30 ng/mL) (n=36)	
Serum testosterone, ng/ml	7.4±2.2	5.3±0.9	0.012
DHEA-S, ng/dL	704.8±102.1	501.6±87.8	0.008
FSH, mIU/mL	6.8±2.3	6.3±1.5	0.773
LH, mIU/mL	18.5±2.1	9.6±0.7	0.001
PRL, ng/mL	23±3.5	15±2.4	0.058
TSH, μ IU/L	2.6±0.8	2.4±0.7	0.981
sT4, pmol/L	11.6±2.1	12.2±3	0.936
Serum testosterone, ng/ml	7.4±2.2	5.3±0.9	0.002
DHEA-S, ng/dL	704.8±102.1,	501.6±87.8	0.011

DHEA-S; Dehydroepiandrosterone Sulfate. FSH; Follicle Stimulating Hormone. LH; *Luteinizing Hormone*. PRL; Prolactin, TSH; Thyroid-Stimulating Hormone, sT4; *Free Thyroxine*. Significant results are shown in bold type.

Table 3: Correlation of 25(OH)D₃ levels and metabolic and endocrine parameters with PCOS.

Parameters	R	P
Age(years)	0.013	0.346
BMI (kg/m ²)	-0.459	0.002
Waist circumference (cm)	-0.315	0.023
Fasting glucose, mg/dl	-0.307	0.031
HOMA-IR	-0.385	0.006
FSH, mIU/mL	-0.134	0.124
LH, mIU/mL	-0.321	0.027
Serum testosterone, ng/ml	-0.374	0.012
DHEA-S, ng/dL	-0.418	0.003
TSH, μ IU/L	0.024	0.652
sT4, pmol/L	0.019	0.514

Discussion

Women diagnosed with PCOS often present with insulin resistance, leading to increased inflammation marker levels, and to a higher risk of type 2 diabetes and cardiovascular disease. These diseases have also been linked to vitamin D deficiency²⁰. The reason for and nature of this association is still not fully understood. The etiopathogenesis of PCOS is a complex phenomenon arising from the interaction of genetic and envi-

ronmental factors²¹. The results of the present study showed that vitamin D deficiency caused increases in the clinical findings and in the metabolic and hormonal profiles of PCOS patients, which is consistent with other studies²². The present study also showed that vitamin D deficiency may be a risk factor or may play a role in the pathophysiology of PCOS. There is a powerful association between insulin resistance and PCOS. Vitamin D is known to be one of the factors leading to the development of insulin resistance^{23, 24}.

An association between PCOS and vitamin D deficiency has been reported in several studies. However, the actual pathogenesis has not yet been elucidated¹⁸. Although the connection between vitamin D deficiency and the underlying causes of PCOS has not yet been clarified, previous studies have revealed a positive correlation between PCOS and body mass index, body fat and insulin resistance^{25, 26}. Previous studies have also revealed that the changes in intracellular calcium concentrations caused by vitamin D deficiency may lead to ovulation and reproductive abnormalities in PCOS¹¹. Statistically significantly higher values for BMI, fasting glucose and HOMA-IR were detected in the vitamin D deficient group in the present research, again in agreement with previous studies ($p < 0.05$). Similarly, a negative correlation was observed between vitamin D levels and BMI, insulin resistance and fasting glucose levels in PCOS patients. The results of the present and previous studies suggest that vitamin D deficiency is a risk factor for PCOS.

PCOS and vitamin D deficiency have been described as risk factors for atherosclerosis and hypertensive disorders. Previous studies have shown that these increase the morbidity and mortality associated with cardiovascular disease²⁷. Vitamin D replacement has also been shown to reduce systolic blood pressure and mortality associated with cardiovascular disease¹⁸.

However, HDL-C levels were higher in the normal vitamin D group than in the insufficient vitamin D group with PCOS ($p < 0.05$). This finding shows that vitamin D normalization may reduce the cardiovascular disease risk in PCOS patients with vitamin D deficiency. In the literature, as in the present study, vitamin D deficiency has been associated with low HDL cholesterol levels^{28, 29}. Previous studies have also reported that vitamin D deficiency is associated with an imbalance in dehydroepiandrosterone-sulfate, and in hyperandrogenism markers such as serum testosterone, free androgen index, free testosterone, and sex hormone-binding globulin^{11, 22, 30}. Serum testosterone, DHEA-S, and LH levels in the present study were higher in Group 1 than in the group with normal vitamin D levels ($p < 0.05$). Our findings show that vitamin D deficiency is linked to a greater increase in androgen hormone levels in PCOS cases. Vitamin D concentrations can serve as a metabolic and hormonal marker in PCOS patients. Replacement therapy with vitamin D has increased insulin sensitivity and reduced androgen levels in PCOS patients with vitamin D deficiency in a number of studies³¹.

TSH and PRL levels increased in Group 1, although

this was not statistically significant ($p > 0.05$). The National Academy of Clinical Biochemistry has recommended that 2.5 $\mu\text{IU}/\text{mL}$ be used rather than 4 $\mu\text{IU}/\text{mL}$ for TSH levels³². We determined a mean TSH level of 2.6 $\mu\text{IU}/\text{mL}$.

Previous studies have shown a connection between PCOS and vitamin D deficiency. There is adequate evidence in the literature to suggest that vitamin D deficiency exacerbates the risk of PCOS^{31, 33}. The fact that the connection between the two cannot be explained may be due to the complex etiology of PCOS. We think that vitamin D deficiency contributes to PCOS development through insulin resistance, obesity, and an increase in androgen levels. Our findings show that vitamin D deficiency represents a risk factor for PCOS. Individuals living in countries in northern latitudes, with insufficient year-round exposure to sunlight (20-30 min a day), and with insufficient vitamin D intake through diet (fish / fish oil and seafood) require vitamin D supplementation. This will eliminate one factor in the complex etiology of PCOS.

Financial support and sponsorship

Nil.

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. Franks S. Polycystic ovary syndrome. *The New England Journal of Medicine*. 1995; 333(13): 853-861.
2. Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. *Endocrine*. 2006; 30(1):45-53.
3. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. *Journal Clinical Endocrinology Metabolism* 1991; 72(1): 83-89.
4. Szczuko M, Zapalowska-Chwyć M, Drozd A, Maciejewska D, Starczewski A, Stachowska E. Effect of IGF-I and TNF- α on intensification of steroid pathways in women with PCOS phenotypes are not identical. Enhancement of progesterone pathway in women with PCOS increases the concentration of TNF- α . *Gynecol Endocrinol*. 2016; 32(9): 714-717.
5. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic

- syndrome in women with polycystic ovary syndrome. *The Journal of Clinical Endocrinology and Metabolism* 2005; 90(4):1929-1935
6. Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. *Fertility Research and Practice* 2016; 2: 14.
 7. Han J, Guo X, Yu X, Liu S, Cui X, Zhang B, et al. 25-Hydroxyvitamin D and Total Cancer Incidence and Mortality: A Meta-Analysis of Prospective Cohort Studies. *Nutrients*. 2019; 11(10): 2295.
 8. Yang J, Ou-Yang J, Huang J. Low serum vitamin D levels increase the mortality of cardiovascular disease in older adults: A dose-response meta-analysis of prospective studies. *Medicine* (Baltimore). 2019; 98(34): e16733.
 9. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. *Autoimmunity Reviews*. 2013; 12(10): 976-89.
 10. Rafiq S, Jeppesen PB. Body Mass Index, Vitamin D, and Type 2 Diabetes: A Systematic Review and Meta-Analysis. *Nutrients*. 2018; 10(9): 1182.
 11. Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG E. et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. *Archives of Gynecology and Obstetrics* 2019; 280(4):559-563
 12. Parikh G, Varadinova M, Suwandhi P, Araki T, Rosenwaks Z, Poretsky L, et al. Vitamin D regulates steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production in human ovarian cells. *Hormone and Metabolic Research* 2010; 42(10): 754-757.
 13. Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. *European Journal of Endocrinology*. 2013; 169(6): 853-65.
 14. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. *Metabolism: clinical and experimental*. 2011;60(10):1475-81. Epub 2011/05/10. doi: 10.1016/j.metabol.2011.03.002. PubMed PMID: 21550088.
 15. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. *Experimental and Clinical Endocrinology and Diabetes* 2006; 114(10): 577-583.
 16. Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, et al. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. *Gynecological Endocrinology*. 2012; 28(12): 965-968.
 17. Al-Hazmi AS. Association of Vitamin D deficiency and Vitamin D Receptor Gene Polymorphisms with Type 2 diabetes mellitus Saudi patients. *African Health Science*. 2019; 19(4): 2812-2818.
 18. He C, Lin Z, Robb SW, Ezeamama AE. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. *Nutrients*. 2015;7(6): 4555-4577.
 19. Geithövel F, Rabe T. The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS)--an extended critical analysis. *Reprod Biomed Online*. 2007; 14(4): 522-535.
 20. Gupta T, Rawat M, Gupta N, Arora S. Study of Effect of Vitamin D Supplementation on the Clinical, Hormonal and Metabolic Profile of the PCOS Women. *Journal of Obstetrics and Gynaecology of India*. 2017; 67(5): 349-55.
 21. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. *Endocrine Reviews*. 2016; 37(5): 467-520.
 22. Skowronska P, Pastuszek E, Kuczynski W, Jaszczol M, Kuc P, Jakiel G, et al. The role of vitamin D in reproductive dysfunction in women - a systematic review. *Annals of Agricultural and Environmental Medicine*. 2016; 23(4): 671-676.
 23. Wang W, Zhang J, Wang H, Wang X, Liu S. Vitamin D deficiency enhances insulin resistance by promoting inflammation in type 2 diabetes. *International Journal of Clinical and Experimental Pathology*. 2019; 12(5): 1859-1867.
 24. Dong B, Zhi M, Han M, Lin H, Yu H, Li L. The relationship between vitamin D and insulin resistance before delivery in advanced maternal age. *Reproductive Biology and Endocrinology*. 2019; 17(1): 108.
 25. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. *The American Journal of Clinical Nutrition*. 2011; 94(2): 486-94.
 26. George PS, Pearson ER, Witham MD. Effect of

- vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. *Diabetic Medicine* 2012; 29(8): e142-e150.
27. van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, et al. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). *Journal of the American College of Cardiology*. 2014; 63(12): 1214-1222.
28. Dibaba DT. Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. *Nutrition Reviews*. 2019; 77(12): 890-902.
29. Sarmiento-Rubiano LA, Angarita Ruidiaz JA, Suarez Davila HF, Suarez Rodriguez A, Rebolledo-Cobos RC, Becerra JE. Relationship between Serum Vitamin D Levels and HDL Cholesterol in Postmenopausal Women from Colombian Caribbean. *Journal of Nutrition and Metabolism*. 2018; 20;2018: 9638317.
30. Shahrokhi SZ, Ghaffari F, Kazerouni F. Role of vitamin D in female reproduction. *Clinica chimica acta; International Journal of Clinical Chemistry*. 2016; 455: 33-8.
31. Karadağ C, Yoldemir T, Yavuz DG. Effects of vitamin D supplementation on insulin sensitivity and androgen levels in vitamin-D-deficient polycystic ovary syndrome patients. *Journal of Obstetrics and Gynaecology Research*. 2018; 44(2): 270-277.
32. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid: official Journal of the American Thyroid Association*. 2003; 13(1): 3-126.
33. Lone NM, Riaz S, Eusaph AZ, Mein CA, Wozniak EL, Xenakis T, et al. Genotypeindependent association between vitamin D deficiency and polycystic ovarian syndrome in Lahore, Pakistan. *Scientific Reports*. 2020; 10(1): 2290